|Assessment process complete
|For the treatment of moderate to severe psoriasis.
|Full submission received from Applicant
|NCPE assessment completed
|NCPE assessment outcome
We consider ustekinumab cost effective for the treatment of moderate to severe plaque psoriasis in the Irish healthcare setting.